Literature DB >> 2934464

Insulin resistance and secretion in polycystic ovarian disease.

B Bruno, G Poccia, A Fabbrini.   

Abstract

In order to verify the relationship between insulin resistance and hyperandrogenism in Polycystic ovary disease (PCOD), circulating levels of insulin in response to oral glucose tolerance test (OGTT) were assessed in 23 PCOD patients and 10 matched control subjects without obesity, acanthosis nigricans and impaired glucose tolerance. In PCOD patients serum total testosterone (T), dehydroepiandrosterone sulfate (DHEA-S), LH and LH/FSH ratio were significantly higher than in control subjects; whereas urinary 17-ketosteroids (17-KS) and glycemic response to OGTT were not different. PCOD patients were clearly hyperinsulinemic before and during OGTT compared to the control group: mean +/- SD basal insulin (Io) (23.4 +/- 10.3 vs 11.3 +/- 4.6 microU/ml, p less than 0.001) and the sums of insulin levels (sigma I) during OGTT (341.4 +/- 148.9 vs 162.2 +/- 56 microU/ml, p less than 0.001). In the two groups serum T, but not DHEA-S, LH, urinary 17-KS and the degree of obesity, was strongly associated with Io (r = 0.458, p less than 0.01) and sigma I (r = 0.419, p less than 0.02), as well as with insulin resistance as assessed by basal (r = 0.425, p less than 0.02) and postglucose challenge (r = 0.384, p less than 0.05) insulin to glucose ratio. These results confirm that the hyperinsulinism and insulin resistance in PCOD is not related to obesity and suggest that the hyperandrogenism may be partially responsible of the observed imbalance in glucose-insulin homeostasis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934464     DOI: 10.1007/BF03348535

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  Evaluation of the obese patient. 1. An algorithm.

Authors:  G A Bray; H A Jordan; E A Sims
Journal:  JAMA       Date:  1976-04-05       Impact factor: 56.272

Review 2.  Receptors, antireceptor antibodies and mechanisms of insulin resistance.

Authors:  J S Flier; C R Kahn; J Roth
Journal:  N Engl J Med       Date:  1979-02-22       Impact factor: 91.245

3.  Platelet-derived growth factor enhances granulosa cell luteinizing hormone receptor induction by follicle-stimulating hormone and serum.

Authors:  J S Mondschein; D W Schomberg
Journal:  Endocrinology       Date:  1981-07       Impact factor: 4.736

4.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-1982. Amenorrhea, virilization, and hyperpigmentation in a 15-year-old girl.

Authors: 
Journal:  N Engl J Med       Date:  1982-06-24       Impact factor: 91.245

5.  The influence of androgens on insulin resistance.

Authors:  D Shoupe; R A Lobo
Journal:  Fertil Steril       Date:  1984-03       Impact factor: 7.329

6.  Insulin resistance in nonobese patients with polycystic ovarian disease.

Authors:  R J Chang; R M Nakamura; H L Judd; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

7.  Hyperinsulinism and insulin resistance in polycystic ovarian syndrome: a verification using oral glucose, I.V. Glucose and tolbutamide.

Authors:  G Cotrozzi; M Matteini; P Relli; T Lazzari
Journal:  Acta Diabetol Lat       Date:  1983 Apr-Jun

8.  Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells.

Authors:  E Y Adashi; A J Hsueh; S S Yen
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

9.  Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone.

Authors:  T L Woodard; G A Burghen; A E Kitabchi; J A Wilimas
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

10.  Abnormalities of fuel metabolism in the polycystic ovary syndrome.

Authors:  J Wortsman; N G Soler
Journal:  Obstet Gynecol       Date:  1982-09       Impact factor: 7.661

View more
  1 in total

1.  Hyperandrogenism, hyperinsulinism and polycystic ovarian disease.

Authors:  R Pasquali; S Venturoli
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.